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Abstract
Background: The incidence and risk factors for hospitalized atrial fibrillation have not been
previously assessed in a national population of dialysis patients.
Methods: We analyzed the United States Renal Data System (USRDS) Dialysis Morbidity and
Mortality Study (DMMS) Wave II in a historical cohort study of hospitalized atrial fibrillation. Data
from 3374 patients who started dialysis in 1996 with valid follow-up times were available for
analysis, censored at the time of renal transplantation and followed until November 2000. Cox
Regression analysis was used to model factors associated with time to first hospitalization for atrial
fibrillation (ICD9 code 427.31x) adjusted for comorbidities, demographic factors, baseline
laboratory values, blood pressures, dialysis modality, and cardioprotective medications.
Results: The incidence density of atrial fibrillation was 12.5/1000 person years. Factors associated
with atrial fibrillation were older age (> = 71 years vs. <48 years), extremes (both high and low) of
pre-dialysis systolic blood pressure, dialysis modality (hemodialysis vs. peritoneal dialysis), and
digoxin use. Baseline use of coumadin was associated with reduced mortality in patients later
hospitalized for atrial fibrillation.
Conclusions: Dialysis patients had a high incidence of atrial fibrillation. This risk was largely
segregated among those with established risk factors for atrial fibrillation, and hemodialysis
patients. Use of coumadin was associated with improved survival among patients later hospitalized
for atrial fibrillation.
Background
Atrial fibrillation is thought to be more common in
chronic dialysis patients than in the general population,
although population based comparisons are not availa-
ble. [1] Atrial fibrillation is worthy of separate study from
other dysrythmias due to unique aspects of its natural his-
tory and management. [1] Risk factors for atrial fibrilla-
tion may be more common in dialysis, and include age,
cardiac enlargement and an abnormal calcium-phospho-
rous metabolism. [2–5] However, the incidence, risk
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factors and associated mortality for hospitalized atrial fi-
brillation have not been reported for a national popula-
tion of chronic dialysis patients. Previous studies have
also not assessed the effects of cardioprotective medica-
tions on atrial fibrillation in dialysis patients. The man-
agement of chronic dialysis patients with atrial fibrillation
is controversial, since studies of atrial fibrillation have
generally excluded patients with chronic renal failure.
[6,7] We therefore performed an historical cohort study of
the United States Renal Data System (USRDS) Dialysis
Morbidity and Mortality Study (DMMS) Wave 2, which
includes information on blood pressure, lipid levels, med-
ications, and other important clinical data. Our objectives
were to determine the incidence, and risk factors for hos-
pitalized atrial fibrillation (primary hospitalization dis-
charge ICD9 code 427.31.x), occurring after the initiation
Table 1: Factors assessed in ESRD patients, DMMS Wave 2, 1996 only
Factor N (%) or mean ± SD Missing (%) Univariate association with 
AFIB
Demographic Factors
N3 3 7 4
Female 1572 (46.6) 0
African American 933 (27.7) 0 0.41 (0.24–0.69)
Mean Age (Years) 58.9 ± 15.9 15 (0.4)
Quartiles of Age (vs. <48) 781
48–60 837 3.54 (1.17–10.76)
61–71 867 6.01 (2.06–17.52)
>71 874 15.26 (5.46–42.66)
Cardiovascular Factors
History of Coronary Heart Disease 1091 (34.9) 250 (7.4) 2.35 (1.60–3.44)
History of Congestive Heart Failure 1150 (36.2) 199 (5.9) 1.80 (1.24–2.61)
Chronic Obstructive Lung Disease 271 (8.6) 229 (6.8) 1.93 (1.13–3.40)
Stroke 336 (10.5) 164 (4.9) 1.69 (1.03–2.81)
Previous CABG 325 (9.6) 118 (3.5) 1.87 (1.14–3.06)
Previous PTCA 174 (5.2) 203 (6.0) 2.43 (1.36–4.35)
Previous coronary angiography 352 (10.4) 302 (9.0) 2.40 (1.51–3.81)
2nd quartile of pre-dialysis SBP (130–146 mm Hg) 
vs. 1st (<130 mm Hg)
0.49 (0.25–0.99)
CKD specific factors
Ever Transplanted (Yes/No) 460 (13.6) NA 0.15 (0.05–0.48)
Peritoneal Dialysis 1662 (49.8) 37 (1.1) 0.59 (0.40–0.86)
Medications
Aspirin (Yes) 628 (18.6) NA
Coumadin 198 (5.9) NA
Beta-blockers NA
Cardioselective 486 (14.4) NA
Non-cardioselective 177 (5.2) NA
Digoxin 142 (4.2) NA 3.72 (2.17–6.38)
Amiodarone 19 (0.6) NA
Calcium Channel Blockers NA
Non-dihyrdopyridine 439 (13.0) NA
Dihydropyridine 1371 (40.6) NA
Statins 310 (9.2) NA
ACE Inhibitors 772 (22.9) NA
Levothyroxine 330 (9.8) NA
In column one, data given as the number (% of total) or mean ± one standard deviation of patients. Univariate odds ratios (with significance testing 
by Chi Square) are the strength of the association of a disease or factor with time to hospitalization for atrial fibrillation (AFIB, ICD9 discharge code 
427.31.x), with 1.0 being neutral.
SBP = systolic blood pressure, DBP = diastolic blood pressure, both in mm/Hg, obtained as the mean of three successive blood pressures. CABG = 
coronary artery bypass graft, PTca = percutaneous transluminal coronary angioplasty LVH = left ventricular hypertrophy, ECHO = echocardiogra-
phy, EKG = electrocardiogram. Statin = HMG-CoA reductase inhibitor, NA = not available since variable was constructed from multiple variables 
(15 in the case of medications). Medication use was assessed at day 60 after initiation of dialysis. Comorbidities such as coronary heart disease and 
congestive heart failure refer to a history of these conditions within ten years prior to the study period. Selective and non-selective beta-blocker 
use does not total since some patients were on both agents Values for continuous variables more than 3 SD above and below the median were 
excluded.BMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/1
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of dialysis but prior to receipt of renal transplantation, as
well as determine risk factors for mortality after hospital-
ized atrial fibrillation.
Methods
A historical cohort study of the USRDS DMMS Wave 2 was
performed. Details on the inception, limitations, validity,
variables and questionnaires used in the study are availa-
ble online at the USRDS researcher's guide website, http:/
/www.usrds.org/research.htm. This database has been
used in many previous cross-sectional [8–11] and longitu-
dinal studies, [12–15] including one by our own institu-
tion. [16] Briefly, DMMS 2 was a prospective cohort study
of a random sample of 20% of all U.S. hemodialysis pa-
tients and virtually all peritoneal dialysis patients starting
treatment in 1996 and early 1997. However, because out-
comes such as hospitalization and mortality had to be
merged with this study from other USRDS files, we did
not consider it a true prospective cohort study for the pur-
poses of this analysis. Characteristics of hemodialysis and
peritoneal dialysis patients (abstracted from prospective
surveys conducted specifically for DMMS 2) were
matched and weighted to allow more appropriate com-
parisons between modalities. Baseline and follow-up data
used in the study are shown in Table 1. In addition, a max-
imum of 15 medications prescribed to each patient at the
study start date (day 60 of dialysis) were recorded. From
this list, the use of beta-blockers (both cardioselective and
non-selective), anti-arrhythmics, coumadin, digoxin,
levo-thyroxine, angiotensin-converting enzyme (ACE) in-
hibitors, calcium channel blockers (subcategorized as di-
hyropyridine and non-dihydropyridine), 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhib-
itors (statins), and aspirin was determined. For purposes
of analysis, cardioselective beta-blockers were atenolol,
betaxolol, bisoprolol, metropolol, and acebutolol.
Carvedilol was approved for use by the FDA in February
1997, and was therefore not assessed. Blood pressure lev-
els, systolic and diastolic, were obtained as the mean of
three readings before and after dialysis, respectively. Pulse
pressure, as the difference between systolic and diastolic
blood pressure, was also assessed as a covariate in
analysis.
Survival status was linked to the DMMS Wave 2 data from
the 2000 USRDS Patients Standard Analysis File (SAF.PA-
TIENTS) via unique patient identifiers assigned by the US-
RDS. The date and cause of death listed in a patient's SAF
was obtained from a form submitted to the USRDS by the
patient's nephrologist (form HCFA 2746). Patient survival
status was complete through 6 November 2000. Hospital-
ization data was complete through 31 December 1999.
Hospitalization data for atrial fibrillation (ICD9 codes
427.31x) were also linked to the DMMS Wave 2 data as
above from SAF.HOSP, using only the first hospitalization
for a given patient during the study period.
Time to hospitalization for atrial fibrillation was defined
as the time from 90 days after the date of the first dialysis
session until the first hospitalization for atrial fibrillation,
censored for death, receipt of renal transplant, loss to fol-
lowup or the end of the study period (which was consid-
ered 31 Dec 1999 since this was the most recent potential
date of hospitalization available in the data files). Survival
Table 2: Unadjusted rates of Atrial Fibrillation by high-risk groups
Patients in each risk group Hospitalized for atrial fibrillation
Age (Quartiles)
> = 71 76 (8.7)
61–70 29 (3.3)
48–60 14 (1.7)
< = 48 4 (0.5)
Pre-Dialysis SBP, mm Hg (Quartiles)
<130 40 (4.4)
130–146 25 (3.3)
147–162 15 (1.9)
>162 43 (5.0)
Hemodialysis 77 (4.6)
Peritoneal Dialysis 46 (2.8)
LVH by ECHO
Yes 20 (5.5)
No 66 (3.6)
Numbers given in the right column are the N(%) of patients in each risk group who were hospitalized for atrial fibrillation during the study period. 
SBP = systolic blood pressure, LVH = left ventricular hypertrophy on echocardiography as specified in the DMMS Wave II facility questionnaire, 
available at http://www.usrds.org/research.htmBMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/1
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time was defined as the time from 90 days after the date
of the first dialysis session until the date of death, cen-
sored for receipt of renal transplant, loss to followup or
the end of the study period (which was considered 6 No-
vember 2000 since this was the most recent date of death
specified in the data files).
Statistical analysis
Univariate analysis was performed with Chi-Square test-
ing for categorical variables (Fisher exact test used for vio-
lations of Cochran's assumptions) and student's t-test for
continuous variables (Mann Whitney test was used for
variables without a Gaussian distribution). Variables with
borderline significance (p value < 0.1 in univariate analy-
sis) and those thought likely to have a clinical relationship
with atrial fibrillation, such as cardioprotective medica-
tions and blood pressure, were entered into the multivar-
iate models. In addition, variables thought to have a likely
clinical relationship with atrial fibrillation were also en-
tered into the multivariate model, in accordance with es-
tablished epidemiological principles. [17] Stepwise
(forward likelihood ratio method) Cox proportional haz-
ards analysis was used to assess the association between
baseline factors and hospitalized atrial fibrillation, inde-
pendent of other factors. Log-log plots were inspected to
verify the existence of proportional hazards. Estimated
hazard ratios (HR) along with corresponding 95% confi-
dence intervals (CI) and p values are reported for all re-
Figure 1
Time to Hospitalization for Atrial Fibrillation by Quartile of pre-dialysis systolic blood pressure (mm Hg), (1 = <130, 2 = 131–
146, 3 = 147–162, 4 = >162). As shown, patients at the extremes of predialysis systolic blood pressure had the greatest risk of 
subsequent hospitalizations for atrial fibrillation.
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gression covariates. Stepwise logistic regression was used
to test the independent association of patient factors with
preexisting coumadin and cardioselective beta-blocker
use, using the same covariates as Cox Regression above.
The association of atrial fibrillation with mortality as a
time-dependent variable was tested by Cox non-propor-
tional hazards regression analysis as previously described.
[18] Hierarchically well-formed models were used in the
assessment of interaction terms. [19] Collinearity diag-
nostics were evaluated both from the output of the statis-
tical procedures and by manual generation of models
including only one of several variables with close relation-
ships (for example, congestive heart failure and left ven-
tricular hypertrophy, which was assessed by chest X-ray,
electrocardiogram, and echocardiography). Propensity
scores [20,21] have been used to adjust for confounding
in baseline medication use. Since this method is primarily
undertaken to assess uniformity of risk among strata,
model fitting was also tested by fitting models to a 70%
random sample of the study population, and then run-
ning the same model for the remaining 30% of the popu-
lation to test for agreement.
Results
A total of 4065 patients were included in the DMMS Wave
2 cohort. Of these, 3621 patients had valid dates for start-
ing dialysis in 1996. From this cohort, 3374 had sufficient
information to calculate follow-up times. During the time
of the study period, 123 patients were hospitalized for a
primary discharge diagnosis of atrial fibrillation, with an
incidence density of 12.5/1000 person years.
Use of digoxin and particularly levothyroxine was com-
mon in dialysis patients. Among other anti-arrhythmic
agents, only amiodarone was used by more than 10 pa-
tients at baseline, and so is the only other agent reported.
Among the study population, cardioselective beta-block-
ers were used by 14.6% of patients hospitalized for atrial
fibrillation vs. 14.4% of all other patients; digoxin was
used by 12% of patients hospitalized for atrial fibrillation
vs. 3.8% of all other patients; and coumadin was used by
8.1% of patients hospitalized for atrial fibrillation vs.
5.6% of all other patients. Characteristics of the study
population, including univariate associations with hospi-
talized atrial fibrillation, are summarized in Table 1. Table
2 shows the percentage of patients who were hospitalized
for atrial fibrillation by risk group. As shown, there were
marked disparities by age, blood pressure, dialysis modal-
ity, and history of left ventricular hypertrophy.
Table 3 shows significant factors associated with hospital-
ized atrial fibrillation in multivariate analysis by Cox Re-
gression. Factors positively associated with atrial
fibrillation were advanced age (> = 71 years vs. age <48
years), hemodialysis (vs. peritoneal dialysis), and baseline
digoxin use. Pre-dialysis systolic blood pressure had a "U"
shaped association with atrial fibrillation, with highest
risk associated with the low and high extremes of blood
Table 3: Cox Regression Analysis of Factors Associated with Hospitalized Atrial Fibrillation
P Value Hazard Ratio 95% CI
Age > = 71 (vs. <48) 0.0002 9.96 2.98–33.28
Hemodialysis (vs. PD) 0.015 2.19 1.17–4.13
Digoxin use (1 = present, 0 = absent) 0.002 3.91 1.65–9.27
Pre-Dialysis SBP, mm Hg (vs. <130)
130–146 0.028 0.37 0.15–0.89
147–162 0.043 0.43 0.19–0.98
SBP = systolic blood pressure, PD = peritoneal dialysis, LVH = left ventricular hypertrophy
Table 4: Survival after Hospitalization for Atrial fibrillation
1-year 2-year 3-year
Survival after hospitalization for 
atrial fibrillationA
75 60 47
Survival for entire cohortB 84 68 55
P valueC <0.01 <0.01 <0.01
Survival given in %. Atrial fibrillation = primary discharge diagnosis ICD9 427.31, N = 123. A Time to hospitalized atrial fibrillation as defined in the 
methods section. B Survival time as defined in the methods section. CBy univariate Cox non-proportional hazards Regression Test, atrial fibrillation 
modeled as a time-dependent variable.BMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/1
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pressure (Figure 1). However, neither pre-dialysis diastol-
ic blood pressure nor post-dialysis blood pressure were
associated with the risk of atrial fibrillation, nor were se-
rum albumin levels. No medications except digoxin were
independently associated with atrial fibrillation. There
were also no significant interactions between terms, spe-
cifically between medications, laboratory data or dialysis
modality in patients with preexisting coronary heart
disease.
There were 1961 total deaths in the cohort through 6 No-
vember 2000. Of the 123 patients hospitalized for atrial
fibrillation, 90 died during the study period. Mean follow-
up was 2.92 ± 1.14 years. Unadjusted survival after atrial
fibrillation and for the entire cohort is also shown in Ta-
ble 4. Survival was significantly worse after atrial fibrilla-
tion in Cox non-proportional hazards regression analysis,
adjusted hazard ratio for mortality, 1.54, 95% confidence
interval, 1.19–1.99, p = 0.001. The leading cause of death
among patients hospitalized for atrial fibrillation was
unknown (26%), followed by cardiac arrest of unknown
cause (19%), cardiac arrthymia (8%), acute myocardial
infarction (7%), atherosclerotic heart disease (6%), cardi-
omyopathy (3%) and stroke (3%). Of patients hospital-
ized for atrial fibrillation, the most common secondary
diagnosis was hypertensive heart disease (15%), followed
by congestive heart failure (11%).
Figure 2
Mortality after hospitalization for Atrial Fibrillation, limited to patients hospitalized for atrial fibrillation (M = 123), stratified by 
patients with baseline coumadin use (COUM) vs. no baseline coumadin use (NO COUM), P < 0.001 by Log Rank Test.
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Table 5 shows Cox Regression analysis of factors signifi-
cantly associated with mortality in patients with hospital-
ized atrial fibrillation. Only two factors, the baseline use
of coumadin (Figure 2) and higher systolic blood pres-
sure, were associated with a lower risk of mortality after
hospitalization for atrial fibrillation. Of note, calcium
channel blockers, specifically non-dihyropyridine calci-
um channel blockers, were not significantly associated
with mortality in patients with atrial fibrillation. In fact,
the hazard ratio for mortality of patients with atrial fibril-
lation using non-dihydropyridine calcium channel block-
ers was 1.85, although the p value was 0.21 and 95%
confidence intervals were 0.69–4.94. Dihydropyridine
calcium blockers, as well as ACE inhibitors and aspirin,
were also not significantly associated with mortality in pa-
tients with atrial fibrillation. Because use of coumadin
might be biased by association with factors favorably as-
sociated with mortality, logistic regression analysis was
performed to assess factors independently associated with
use of coumadin. However, only three factors were inde-
pendently associated with the use of coumadin: left ven-
tricular hypertrophy on echocardiography (adjusted odds
ratio, 1.88, 95% CI, 1.10–3.20, p = 0.02); chronic obstruc-
tive lung disease (adjusted odds ratio, 1.98, 95% CI, 1.05–
3.74); and aspirin use (adjusted odds ratio, 0.31, 95% CI,
0.14–0.67, p = 0.002). When Cox regression analysis was
performed limited to patients who had left ventricular
hypertrophy, chronic obstructive lung disease, or did not
use aspirin (N hospitalized for atrial fibrillation = 87),
coumadin use was still significantly associated with im-
proved survival, adjusted hazard ratio, 0.36, 95% CI,
0.16–0.82, p = 0.014. Models were robust to testing on
random samples of the study population (70% vs. the re-
maining 30%).
Discussion
In agreement with some previous studies in the general
population [1,4] and preliminary reports from the US-
RDS, [22] atrial fibrillation was associated with increased
mortality among chronic dialysis patients. In the general
population, cardiovascular events, and not thromboem-
bolic events, are the most common cause of death after
atrial fibrillation, [23] in agreement with the findings of
the present analysis. However, it is also possible that
thromboembolic events could have been underdiagnosed
due to a low index of suspicion for thromboembolism in
chronic dialysis patients, [24–26] because of the high
number of deaths with an unknown cause, the low rate of
autopsies in this population, or a combination of these
factors. Vazquez et al [5] provide further evidence that
causes of death may underestimate the incidence of em-
bolic events in chronic dialysis patients with atrial fibrilla-
tion. They reported that 35% of chronic dialysis patients
with atrial fibrillation suffered thromboembolic events at
one year of followup.
Risk factors for atrial fibrillation in chronic dialysis pa-
tients were consistent with established risk factors
[4,5,27], except for the association with hemodialysis
(compared with those on peritoneal dialysis). In addition
to age, left ventricular hypertrophy is also a well-estab-
lished risk factor for atrial fibrillation in the general pop-
ulation. Many markers for cardiovascular comorbidity
were associated with atrial fibrillation in univariate analy-
sis (Table 1), but not in multivariate analysis (Table 3).
While the efficacy of cardioversion in successful conver-
sion of atrial dysrythmias may be helpful in some settings,
it is less useful than the duration of the dysrythmia in pa-
tients with atrial fibrillation. [28] However, it has never
been established whether the same guidelines apply to di-
alysis patients. The present study could not assess whether
cardiac enlargement affected the success rate of cardiover-
sion in dialysis patients hospitalized for atrial fibrillation.
Pre-dialysis systolic blood pressure exhibited a "U"
shaped relationship with the risk of atrial fibrillation,
which is similar to the "U" shaped relationship of blood
pressure with mortality and other cardiovascular events in
chronic dialysis patients. Recent reports have indicated
that pulse pressure is a more predictive indicator of cardi-
ovascular events in dialysis patients than either systolic or
diastolic blood pressure separately. [29] However, pulse
pressure was not independently associated with atrial fi-
brillation in our analysis.
Hemodialysis was associated with a significantly higher
risk of atrial fibrillation than peritoneal dialysis in the
present study. It is possible this association represents bi-
as, since hemodialysis patients present for medical care
much more frequently than peritoneal dialysis patients,
and asymptomatic atrial fibrillation is more readily de-
tected. However, there are legitimate reasons why atrial fi-
brillation might occur more frequently on hemodialysis
than on peritoneal dialysis. First, Foley et al demonstrated
that progressive cardiac enlargement was more frequent in
hemodialysis patients than peritoneal dialysis patients,
[2] although these findings were not replicated in a Japa-
nese study. [30] Other investigators have confirmed that
LVH progresses despite adequate blood pressure control
in hemodialysis patients. [31] Also, hospitalized conges-
tive heart failure is more common in hemodialysis than
peritoneal dialysis patients, especially for those on the re-
nal transplant waiting list. [32] The typical regimen for
hemodialysis is likely far less physiologic than peritoneal
dialysis. Residual renal function may also be preserved
longer in patients on peritoneal dialysis, although this is
controversial. [33,34] Some or all of these factors may
therefore mediate the higher risk of atrial fibrillation asso-
ciated with hemodialysis.BMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/1
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The effectiveness of coumadin for atrial fibrillation in
chronic dialysis patients has not been assessed previously.
In fact, previous reports considered chronic renal failure a
contraindication to the use of anticoagulation in atrial fi-
brillation. [35] Wiesholzer et al concluded that non-rheu-
matic atrial fibrillation was not an independent risk factor
for stroke in dialysis patients. [36] Therefore, Figure 2 sug-
gests several possibilities. First, although the clinical indi-
cations for coumadin use in this cohort were unknown,
coumadin is often given for a limited period of time [31],
after which it is often discontinued, in the absence of
known predisposing factors. Therefore, patients who were
using coumadin at the time of the study assessment and
later discontinued it might not have been taking couma-
din at the time they were hospitalized for atrial fibrilla-
tion, negating a possible beneficial association of
coumadin with mortality after hospitalization for atrial fi-
brillation. Another possibility is that many patients not
taking coumadin at baseline may have later been treated
with coumadin after hospitalization for atrial fibrillation.
Given the growing evidence that dialysis patients in the
modern era may actually be hypercoagulable, primarily
due to defects of the fibrinolytic system, [25,37,38] clini-
cal trials of the use of anticoagulation in atrial fibrillation
and thromboembolic disorders are warranted. Of note,
baseline coumadin use, in contrast to digoxin use, was not
associated with hospitalization for atrial fibrillation and
therefore presumably was not a marker for patients with
pre-existing atrial fibrillation.
The decision to use coumadin in patients with atrial fibril-
lation in whom NSR cannot be established is based on an
assessment of both their risk of serious bleeding and their
risk of stroke. Coumadin therapy has been associated with
improved survival in patients with reduced LV systolic
dysfunction in the absence of dysrythmias as well, prima-
rily through reduction in cardiovascular events rather than
reduction of thromboembolic events. [39] This may be
one explanation for the association of coumadin use with
reduced mortality in chronic dialysis patients hospitalized
for atrial fibrillation in the present study.
Study limitations
The present study was observational and not randomized,
and therefore associations should not be construed as
causative. The study is a random sample of all hemodial-
ysis patients, not the total population, although the peri-
toneal dialysis population was almost fully captured. We
did not have access to information on treatment or con-
version to NSR in patients who were hospitalized for atrial
fibrillation, nor did we have information on the type of
atrial fibrillation for which patients presented and how it
was classified within ACC/AHA/ESC guidelines. [40] We
did not have access to information on which patients had
self-limited episodes of atrial fibrillation vs. those who
had persistent atrial fibrillation, nor the duration or pres-
ence of atrial fibrillation prior to hospitalization or the
study start. We did not have information on left atrial size
other than the presence of LVH on echocardiography. We
also did not have information on thyroid functions (other
than baseline use of thyroxine), alcohol use, or pre-exist-
ing atrial dysrythmias. Information bias could have arisen
due to mistakes in coding or spelling, especially for med-
ications. We were unable to follow changes in variables
over time. Therefore, we could not follow changes in
blood pressure, laboratory values, dialysis adequacy, or
medications. We could not assess other factors that have
shown to be associated with atrial fibrillation, such as hy-
pokalemia or calcified aortic/mitral valves, [41] although
there are many similarities between the risk factors for val-
vular heart disease and atrial fibrillation in chronic dialy-
sis patients. [42] Our use of atrial fibrillation as an
outcome variable required survival to reach hospitaliza-
tion, and thus sudden death was not considered as an out-
come. However, causes of death, especially if not verified
by autopsy, are also of questionable validity in compari-
son to the rates of total mortality. [43]
In summary, the present observational, non-randomized
study confirms the high incidence and mortality of atrial
fibrillation in chronic dialysis patients. Traditional risk
factors for atrial fibrillation such, as older age, were con-
firmed. Hemodialysis, possibly due to a greater frequency
of progressive cardiac enlargement or more frequent ob-
servation, was also identified as a risk factor for atrial fi-
brillation. Of the greatest potential importance, the use of
Table 5: Cox Regression Analysis of Factors Associated with Mortality in Patients with Hospitalized Atrial Fibrillation
P Value Hazard Ratio 95% CI
Coumadin use Quartiles of Predialysis SBP, 
mm Hg (vs. <130)
0.014 0.39 0.18–0.83
Quartiles of Predialysis SBP, mm Hg (vs. <130)
130–146 0.012 0.44 0.23–0.84
>162 0.024 0.53 0.31–0.83BMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/1
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coumadin at the start of the study was associated with
lower mortality in patients later hospitalized for atrial fi-
brillation. These findings should be confirmed in clinical
trials.
Author' contributions
KCA conceived the original concept, performed the anal-
yses, and wrote most of the manuscript
FCT collaborated in the manuscript and was instrumental
in the initial preparation of DMMS 2 files for analysis, es-
pecially medications
AJT collaborated in the manuscript providing background
on atrial fibrillation and its role in chronic renal failure.
LYA, as Project Director for the NIDDK, is a world expert
on the USRDS and was instrumental in the interpretation
of USRDS files.
Competing interest
None declared
References
1. Zebe H Atrial fibrillation in dialysis patients.  Nephrol Dial
Transplant 2000, 15:765-8
2. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC and Barre PE
Long-term evolution of cardiomyopathy in dialysis patients.
Kidney Int 1998, 54:1720-5
3. Ansari N, Manis T and Feinfeld DA Symptomatic atrial arrhyth-
mias in hemodialysis patients. Ren Fail 2001, 23:71-6
4. Fabbian F, Catalano C, Lambertini D, Tarroni G, Bordin V, Squerzanti
R, Gilli P, Di Landro D and Cavagna R Clinical characteristics as-
sociated to atrial fibrillation in chronic hemodialysis
patients. Clin Nephrol 2000, 54:234-9
5. Vazquez E, Sanchez-Perales C, Borrego F, Garcia-Cortes MJ, Lozano
C, Guzman M, Gil JM, Borrego MJ and Perez V Influence of atrial
fibrillation on the morbido-mortality of patients on
hemodialysis. Am Heart J 2000, 140:886-90
6. SPAF Investigators The Stroke Prevention in Atrial Fibrillation
Study Group Investigators: final results.  Circulation 1991,
84:527-39
7. Stroke Prevention in Atrial Fibrillation investigators Adjusted-dose
warfarin versus low-intensity, fixed-dose warfarin plus aspi-
rin for high-risk patients with atrial fibrillation: Stroke Pre-
vention in Atrial Fibrillation III randomised clinical trial.
Lancet 1996, 348:633-8
8. Stack AG and Bloembergen WE Prevalence and clinical corre-
lates of coronary artery disease among new dialysis patients
in the United States: a cross-sectional study. J Am Soc Nephrol
2001, 12:1516-23
9. Stack AG and Bloembergen WE A cross-sectional study of the
prevalence and clinical correlates of congestive heart failure
among incident US dialysis patients.  Am J Kidney Dis 2001,
38:992-1000
10. Stehman-Breen CO, Gillen D and Gipson D Prescription of hor-
mone replacement therapy in postmenopausal women with
renal failure. Kidney Int 1999, 56:2243-7
11. Stehman-Breen CO, Sherrard DJ, Gillen D and Caps M Determi-
nants of type and timing of initial permanent hemodialysis
vascular access. Kidney Int 2000, 57:639-45
12. [No authors listed] Medication use among dialysis patients in
the DMMS. United States Renal Data System. Dialysis Mor-
bidity and Mortality Study. Am J Kidney Dis 1998, 32(2 Suppl
1):S60-8
13. Fung F, Sherrard DJ, Gillen DL, Wong C, Kestenbaum B, Seliger S, Ball
A and Stehman-Breen C Increased risk for cardiovascular mor-
tality among malnourished end-stage renal disease patients.
Am J Kidney Dis 2002, 40:307-14
14. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ
and Stehman-Breen CO HMG-CoA reductase inhibitors are as-
sociated with reduced mortality in ESRD patients. Kidney Int
2002, 61:297-304
15. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A and Stehman-
Breen C Calcium channel blocker use and mortality among
patients with end-stage renal disease. Kidney Int 2002, 61:2157-
64
16. Trespalacios FC, Taylor AJ, Agodoa LY and Abbott KC Incident
acute coronary syndromes in chronic dialysis patients in the
United States. Kidney Int 2002, 62:1799-1805
17. Szklo M and Nieto FJ Epidemiology: Beyond the Basics. Chapter
7, "Stratification and Adjustment: Multivariate Analysis in Epidemiology,"
page 257. © Aspen Publishers, Gaithersburg, MD 2000, 
18. Hypolite IO, Bucci J, Hshieh P, Cruess D, Agodoa LY, Yuan CM, Tay-
lor AJ and Abbott KC Acute coronary syndromes after renal
transplantation in patients with end-stage renal disease re-
sulting from diabetes. Am J Transplant 2002, 2:274-81
19. David Kleinbaum G Survival Analysis : A Self-Learning Text (Statistics in
the Health Sciences) Springer Verlag; New York, New York May 1996
20. Mehta RL, McDonald B, Gabbai F, Pahl M, Farkas A, Pascual MT,
Zhuang S, Kaplan RM and Chertow GM Nephrology consultation
in acute renal failure: does timing matter? Am J Med 2002,
113:456-61
21. Stata corporation [http://www.iue.it/Personal/Ichino/psj7.pdf] 
22. Wattigney WA, Mensah GA and Croft JB Increased atrial fibrilla-
tion mortality: United States, 1980–1998. Am J Epidemiol 2002,
155:819-26
23. Casserly LF, Reddy SM and Dember LM Venous thromboembo-
lism in end-stage renal disease. Am J Kidney Dis 2000, 36:405-11
24. Tveit DP, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG
and Abbott KC Chronic dialysis patients have high risk for pul-
monary embolism. Am J Kidney Dis 2002, 39:1011-7
25. Tveit DP, Hshieh P, Cruess D, Agodoa LY, Welch PG and Abbott KC
Risk factors for pulmonary embolism in chronic dialysis
patients. J Nephrol 2002, 15:241-7
26. Fumagalli S, Boncinelli L, Bondi E, Caleri V, Gatto S, Di Bari M, Bald-
ereschi G, Valoti P, Masotti G and Marchionni N Does advanced
age affect the immediate and long-term results of direct-cur-
rent external cardioversion of atrial fibrillation? J Am Geriatr
Soc 2002, 50:1192-7
27. Asinger RW Role of transthoracic echocardiography in atrial
fibrillation. Echocardiography 2000, 17:357-64
28. Tozawa M, Iseki K, Iseki C and Takishita S Pulse pressure and risk
of total mortality and cardiovascular events in patients on
chronic hemodialysis. Kidney Int 2002, 61:717-26
29. Takeda K, Nakamoto M, Baba M, Tanaka T, Yasunaga C, Nishihara G,
Matsuo K and Urabe M Echocardiographic evaluation in long-
term continuous ambulatory peritoneal dialysis compared
with the hemodialysis patients. Clin Nephrol 1998, 49:308-12
30. Covic A, Goldsmith DJ, Georgescu G, Venning MC and Ackrill P
Echocardiographic findings in long-term, long-hour hemodi-
alysis patients. Clin Nephrol 1996, 45:104-10
31. Abbott KC, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG,
Taylor AJ and Yuan CM The impact of renal transplantation on
the incidence of congestive heart failure in patients with end-
stage renal disease due to diabetes. J Nephrol 2001, 14:369-76
32. Buoncristiani U, Fagugli R, Ciao G, Ciucci A, Carobi C, Quintaliani G
and Pasini P Left ventricular hypertrophy in daily dialysis. Miner
Electrolyte Metab 1999, 25:90-4
33. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW and
Krediet RT Predictors of the rate of decline of residual renal
function in incident dialysis patients. Kidney Int 2002, 62:1046-
1053
34. Lip GY, Tean KN and Dunn FG Treatment of atrial fibrillation in
a district general hospital. Br Heart J 1994, 71:92-5
35. Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D and Balcke P
Incidence of stroke among chronic hemodialysis patients
with nonrheumatic atrial fibrillation. Am J Nephrol 2001, 21:35-9
36. Oda H, Ohno M and Ohashi H Coagulation and fibrinolysis fac-
tors in dialysis patients with and without ischemic heart
disease. Adv Perit Dial 2000, 16:152-5Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/1
Page 10 of 10
(page number not for citation purposes)
37. Lottermoser K, Petras S, Poge U, Fimmers R, Hertfelder HJ, Sch-
iermeyer B, Vetter H and Dusing R The fibrinolytic system in
chronic renal failure. Eur J Med Res 2001, 6:372-6
38. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ and Kons-
tam MA Warfarin anticoagulation and survival: a cohort anal-
ysis from the Studies of Left Ventricular Dysfunction. J Am Coll
Cardiol 1998, 31:749-53
39. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL,
Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky
EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon
DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO,
Smith SC Jr, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C,
de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S
and Torbicki A ACC/AHA/ESC Guidelines for the Manage-
ment of Patients With Atrial Fibrillation: Executive Summa-
ry A Report of the American College of Cardiology/
American Heart Association Task Force on Practice Guide-
lines and the European Society of Cardiology Committee for
Practice Guidelines and Policy Conferences (Committee to
Develop Guidelines for the Management of Patients With
Atrial Fibrillation) Developed in Collaboration With the
North American Society of Pacing and Electrophysiology.
Circulation 2001, 104(17):2118-50
40. Korzets A, Ori Y and Herman M Serum potassium levels and
atrial fibrillation in haemodialysis patients.  Nephrol Dial
Transplant 2001, 16:1090Letter
41. Abbott KC and Agodoa LY Hospitalizations for valvular heart
disease in chronic dialysis patients in the United States. Ne-
phron 2002, 92:43-50
42. Schall LC, Buchanich JM, Marsh GM and Bittner GM Utilizing mul-
tiple vital status tracing services optimizes mortality follow-
up in large cohort studies. Ann Epidemiol 2001, 11:292-296
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2369/4/1/prepub